Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA) from its SEC filings: 2023 revenue $0, free cash flow -$5.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2023) | $0 |
| Net income | -$5.3 million |
| Free cash flow | -$5.0 million |
| Diluted EPS | $-0.37 |
| Cash | $268.5 million |
| Share count, 1 year | +77% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.